Treating cold sores with anti-virals ‘may slash risk of developing Alzheimer's'
Previous studies have found that the herpes simplex virus type 1 (HSV-1) can lie dormant in human cells for a lifetime before 're-awakening', leading to dementia symptoms.
Experts have discovered that HSV-1 causes changes that resemble those in the brains of dementia patients, such as amyloid plaque-like formations and inflammation.
Now, a large US study suggests that treating HSV-1 may be a route to lessening the risk of Alzheimer's disease.
Researchers, including from pharmaceutical firm Gilead Sciences and the University of Washington in Seattle, used data on 344,628 people with Alzheimer's matched with the same number of people without the disease.
All were aged over 50 and the diagnosis of Alzheimer's was made between 2006 and 2021.
A history of HSV-1 diagnosis was noted for 1,507 (0.44%) patients with Alzheimer's, compared with 823 (0.24%) of those without.
Nearly two thirds (65%) of those with Alzheimer's disease were women, with an average age if 73.
The study found that people who had suffered the herpes virus had an 80% increased risk of Alzheimer's, even when other factors were taken into account.
But those with HSV-1 who used anti-virals to treat the virus were 17% less likely to develop Alzheimer's compared with those who did not the medicines.
Among the 2,330 people with a history of HSV-1 infection, 931 (40%) used anti-virals after their diagnosis.
The authors, writing in the journal BMJ Open, concluded: 'Findings from this large…study implicate HSV-1 in the development of Alzheimer's disease and highlight anti-herpetic therapies as potentially protective for Alzheimer's and related dementia.'
In the UK, the drug aciclovir is one of those available for treating cold sores, chickenpox, shingles and other herpes virus infections.
The researchers also looked at the potential role of other herpes viruses, including HSV-2, varicella zoster virus (which causes chickenpox), and cytomegalovirus.
Both HSV-2 and varicella zoster virus infections were also associated with a heightened risk of Alzheimer's disease.
Exactly how HSV-1 and other viruses might heighten the risk of dementia is not clear, point out the researchers.
'However, studies have shown that inflammatory alterations in the brain caused by HSV infection are pivotal in (Alzheimer's disease) development,' they added.
HSV-1 DNA is also found in the plaques characteristic of Alzheimer's disease, and people carrying the most common genetic risk factor for the disease are more susceptible to HSV infections, they said.
Professor Tara Spires-Jones, from the University of Edinburgh, said: 'This is a well-conducted study adding to strong data in the field linking HSV-1 and other viral infections to increased risk of developing Alzheimer's disease, but it is important to note that HSV-1 infection, which is extremely common in the population, is by no means a guarantee that someone will develop Alzheimer's.
'Why viral infections may increase risk of dementia is not fully understood, but the most likely explanation is that infections increase inflammation in the body and contribute to age-related brain inflammation.
'More research is needed to understand the best way to protect our brains from Alzheimer's disease as we age, including a better understanding of links between viral infection and Alzheimer's risk.'
Dr David Vickers, from the University of Calgary in Canada, said the 'research exaggerates the role of HSV-1, failing to appreciate its absence in 99.56% of Alzheimer's disease cases'.
He added: 'The observed 17% hazard reduction with anti-herpetic drugs translates to a mere nine-month delay in Alzheimer's disease onset.'
Dr Richard Oakley, director of research and innovation at the Alzheimer's Society, said: 'Results from this observational study suggested that people with recorded cold sore infections were more likely to develop Alzheimer's disease, and interestingly those prescribed antiviral drugs had a slightly lower risk.
'But this doesn't prove that cold sores cause Alzheimer's disease, or that anti-virals prevent it.
'The data came from insurance records, often based on self-reported symptoms which may miss or misclassify infections, and didn't track how often people had cold sores or how consistently they took medication.
'Much more research is needed to explore exactly how viruses might be involved and before we can draw firm conclusions.'
Dr Sheona Scales, director of research at Alzheimer's Research UK, welcomed the study but said more research was needed.
'We know there are 14 established risk factors for dementia, and there's not enough evidence to include infections in this list.
'This study doesn't tell us if infections are causing the risk, it only shows an association. Further research is needed to understand what the underlying biology around this is.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Covid-19 Vaccine Guidelines Are Changing. What We Know About Who Can Get a Shot.
It's late August, there's a hurricane coming up the East Coast, schools are starting to open, and no one has any idea who can get an updated Covid-19 shot. It has killed up to 56,000 people in the U.S. since last October, according to the Centers for Disease Control and Prevention, and sickened up to 18 million. Pfizer Moderna and Novavax all plan to launch new versions of their Covid-19 vaccines this fall, updated to target a family of Covid-19 viruses called JN.1.
Business Wire
3 hours ago
- Business Wire
New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript, titled 'A Phase 3 Trial of Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis' Following the online publication in NEJM, the manuscript will be available on the Congresses & Publications page of the Company's corporate website. 'IMPALA-2, the largest and longest Phase 3 clinical trial conducted in patients with autoimmune PAP, demonstrated that 48 weeks of once daily administration of inhaled molgramostim addresses the underlying pathophysiology of this chronic rare lung disease,' said Bruce Trapnell, M.D., Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine and Lead Clinical Investigator of the IMPALA-2 trial. 'Treatment with molgramostim improved the cardinal manifestations of autoimmune PAP, namely it reduced pulmonary surfactant burden and improved pulmonary gas transfer, respiratory health-related quality of life, and patient functionality. Additionally, molgramostim was well tolerated with no notable safety concerns.' IMPALA-2 achieved statistical significance on its primary endpoint, change from baseline in the hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide (DLco%) at Week 24. Molgramostim significantly improved pulmonary gas transfer as measured by DLco% at Week 24 compared with placebo (9.8% vs. 3.8%; estimated treatment difference, 6.0%; P<0.001 by comparison of least-squares means [LSMs]). The beneficial effect of molgramostim on pulmonary gas transfer was maintained to Week 48 as shown by the difference in LSM change from baseline in DLco% at Week 48 between molgramostim and placebo groups (11.6% vs. 4.7%; estimated treatment difference, 6.9%; P<0.001). The mean improvements in DLco% from baseline for molgramostim (9.8% at Week 24 and 11.6% at Week 48) are similar to the minimal clinically meaningful difference (MCID) in DLco% of 10% reported for pulmonary fibrosis. 1 Molgramostim improved respiratory health-related quality of life as measured by the St. George's Respiratory Questionnaire (SGRQ) Total and Activity scores. The magnitude of LSM reduction from baseline in SGRQ Total score was significantly greater in the molgramostim group than placebo at Week 24 (-11.5 points vs. -4.9 points, estimated difference, -6.6 points; P=0.007) and remained numerically greater at Week 48 (-10.7 points vs. -5.9 points, estimated difference, -4.9 points [95% confidence interval, -10.8, 1.0]). The LSM change from baseline in SGRQ Activity score was greater for molgramostim compared with placebo at Week 24 (-13.0 points vs. -5.2 points, estimated difference, -7.8 points [95% confidence interval, -14.1, -1.5]) and at Week 48 (-13.4 vs. -7.4 points, estimated difference, -6.0 points [95% confidence interval, -13.6, 1.6]). Molgramostim improved patient function as measured by exercise capacity (expressed as peak metabolic equivalents [METs]). A MET is a unit of resting oxygen uptake which measures energy expenditure. The LSM change from baseline in peak-METs was greater at Week 48 for molgramostim than placebo (1.1 vs. 0.6; estimated treatment difference, 0.6; [95% confidence interval, 0.1, 1.0]). Peak-METs is a clinically useful unit of measure reflecting exercise capacity, prognosis, and mortality in cardiovascular disease for which a 0.5-MET increase comprises a clinically useful measure of rehabilitation. 2 Using the treadmill test in IMPALA-2, the LSM change in peak-METs from baseline to Week 48 was 1.1 in molgramostim-treated patients and the between-group difference observed at Week 48 was 0.6 peak-METs. Molgramostim reduced surfactant burden as measured by ground glass opacity (GGO) score, an exploratory endpoint in IMPALA-2; GGO scores were determined by two blinded radiologists from a chest CT scan, with scores ranging from 0 to 15 (higher scores are worse). The mean reduction from baseline in GGO score was greater in the molgramostim group than the placebo group at Week 24 (-2.1 vs -1.1). Further, the number of patients who received ≥1 whole lung lavage as rescue therapy during the double-blind intervention period was lower with molgramostim than placebo (6 [7%] vs. 11 [13%]). In IMPALA-2, molgramostim was well tolerated. Most treatment-emergent adverse events (AEs) were mild or moderate, and few led to discontinuation, with 98% of patients in the molgramostim group and 96% of patients in the placebo group completing the 48-week double-blind period on treatment. About IMPALA-2 IMPALA-2 was a global, pivotal, Phase 3, 48-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the efficacy and safety of molgramostim 300 mcg self-administered once daily by inhalation with matching placebo in patients with autoimmune PAP. The trial was conducted at 43 clinical trial sites across 16 countries, including the U.S., Canada, Japan, South Korea, Australia, and countries in Europe, including Turkey. The primary efficacy assessment was hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide (DLco%), a gas transfer measure, and the primary endpoint was change from baseline to Week 24 in percent predicted DLco%, with a secondary endpoint of change from baseline to Week 48 in percent predicted DLco%. Three additional secondary efficacy variables evaluated clinical measures of patient benefit: St. George's Respiratory Questionnaire (SGRQ) Total score, SGRQ Activity score, and exercise capacity using a treadmill test, with each endpoint measured at Weeks 24 and 48. The primary time point for efficacy assessments was at Week 24; however, efficacy was assessed through Week 48 to evaluate durability of effect. Safety was assessed through Week 48. All patients who completed the 48-week double-blind treatment period continued into a 96-week open-label period during which molgramostim 300 mcg is administered once daily. Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas transfer, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim), is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at and LinkedIn. 1 Raghu G, et al. Am J Respir Crit Care Med 2022;205:e18-e47. 2 Ross R, et al. Circulation 2016;134:e653-e99; Grace SL, et al. Can J Cardiol 2014;30:945-8; Kehler DS, et al. J Cardiopulm Rehabil Prev 2017;37:250-6.
Yahoo
4 hours ago
- Yahoo
Exclusive-CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists
By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medicine's proven effectiveness. CVS based the decision on clinical, financial, and regulatory factors, spokesperson David Whitrap said in an email. It also will not cover Yeztugo under its Affordable Care Act formularies, since its ACA preventive program follows recommendations and mandates from the U.S. Department of Health and Human Services (HHS), Whitrap said. Current HIV prevention recommendations from the U.S. Preventive Services Task Force (USPSTF), which is supported by HHS, include only three older drugs. A source familiar with the situation suggested that Gilead is still negotiating with CVS over Yeztugo, a twice-yearly injection with a U.S. list price of more than $28,000 a year. The decision by CVS is "a grave disappointment and frankly a missed opportunity," said Mitchell Warren, executive director of the AIDS nonprofit AVAC. "It does reflect a price that is too high and a U.S. pharmaceutical pricing structure that is frankly not sustainable." He and other AIDS activists have said Yeztugo could be a transformative tool in ending the 44-year-old epidemic that infects 1.3 million people a year and is estimated by the World Health Organization to have killed more than 42 million. Pharmacy benefit managers, or PBMs, act as middlemen between drug companies and consumers. They negotiate volume discounts with drug manufacturers on behalf of employers and health plans based on coverage terms. The three largest - CVS Caremark, UnitedHealth Group's OptumRX and Cigna's Express Scripts - control about 70% of specialty drug prescriptions in the U.S. Optum said Yeztugo will be reviewed for coverage in the coming weeks, while Express Scripts did not respond to requests for comment. Gilead, which declined to comment, said earlier this month it is on track to secure 75% U.S. insurer coverage of Yeztugo by year-end and 90% coverage by June 2026. Its CEO, Daniel O'Day, has said that half of every dollar spent on medicines in the U.S. goes to PBMs and other entities that do not make drugs. U.S. government healthcare programs, including the Veterans Administration and the Medicare program for people over age 65, have already added Yeztugo to coverage lists. Gilead said earlier this month that several state-run Medicaid plans, including California and New York, were covering the drug. Gilead, its investors, and AIDS activists have high hopes for Yeztugo. Approved in June for people at high risk of HIV, the drug was shown to be nearly 100% effective at preventing infection in large trials, fueling fresh optimism about limiting the spread of HIV. Some analysts have warned that a recent Supreme Court ruling affirming broad HHS authority over the USPSTF could affect coverage prospects while Robert F. Kennedy Jr is in charge of the agency. Medical groups have expressed alarm about reports that Kennedy could replace members of the task force. The 16-member task force reviews evidence and public input, then recommends preventive services that catch disease early or prevent worsening, which insurers must cover without patient cost-sharing. For HIV prevention, it endorses daily PrEP pills Truvada, which is available as a generic, and Gilead's Descovy, as well as ViiV Healthcare's bimonthly shot Apretude. Gilead's O'Day has stressed that the lifetime cost of treating an HIV patient can exceed $1 million, making a preventive treatment cost effective. (Reporting By Deena Beasley; Editing by Patrick Wingrove and Diane Craft) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
